| Literature DB >> 35024180 |
Qing Zhang1, Jia Liu1, Huxinyue Duan1, Ruolan Li1, Wei Peng1, Chunjie Wu1.
Abstract
Introduction: Recently, Nrf2/HO-1 has received extensive attention as the main regulatory pathway of intracellular defense against oxidative stress and is considered an ideal target for alleviating endothelial cell (EC) injury.Entities:
Keywords: 7-HMR, (−)-7(S)-hydroxymatairesinol; ADH, andrographolide; AGE, advanced glycation end product; AMP, Athyrium Multidentatum; APV, aqueous extracts of Prunella Vulgaris; ARE, antioxidant reaction elements; AS, atherosclerosis; ASD-IV, Astragaloside IV; ASP, Angelica sinensis polysaccharide; ASTP, Astragalus polysacharin; Akt, protein kinase B; Ang, Angiotensin; ApoE, apolipoprotein E; Atherosclerosis; BAECs, bovine artery endothelial cells; BBR, Berberine; BITC, benzyl isothiocyanate; C3G, Cyanidin-3-O-glucoside; CINM, Cinnamaldehyde; CNC, Cap'n'collar; CREB, cAMP-response element binding protein; CVDs, cardiovascular diseases; CVRF, cardiovascular risk factors; DMY, Dihydromyricetin; ECC, (−)-Epicatechin; ECs, endothelial cells; EGCG, epigallocatechin-3-O-gallate; ERK, extracellular regulated protein kinases; ET, endothelin; EXS, Xanthoceras sorbifolia; FFA, Fatty Acids; GPx, Glutathione peroxidase; GSD Rg1, Ginsenoside Rg1; GTE, Ganoderma tsugae extracts; Gau A, Glaucocalyxin A; HAMS, human anthocyanin medicated serum; HG, high glucose; HIF-1, Hypoxia-inducible factor 1; HO-1, heme oxygenase; HUVECs, human umbilical vein endothelial cells; HXC, Huoxue capsule; Hcy, Homocysteine; Herbal medicine; ICAM, intercellular adhesion molecule; IL, interleukin; KGRE, extracts of KGR; KRG, Korean red ginseng; Keap1, kelch-like epichlorohydrin-related proteins; LWDH, Liuwei-Dihuang pill; MA, maslinic acid; MAPKK, mitogen-activated protein kinase kinase; MAPKs, mitogen-activated protein kinases; MCGA3, 3-O-caffeoyl-1-methylquinic acid; MCP-1, monocyte chemotactic protein 1; MMPs, matrix metalloproteinases; Molecular mechanism; NAF, Nepeta Angustifolia; NF-κB, nuclear factor kappa-B; NG, naringenin; NQO1, NAD(P)H: quinone oxidoreductase; Nrf2, nuclear factor erythroid-2 related factor 2; Nrf2/HO-1 signaling; OA, Oleanolic acid; OMT, Oxymatrine; OX-LDL, oxidized low density lipoprotein; Oxidative stress; PA, Palmitate; PAA, Pachymic acid; PAI-1, plasminogen activator Inhibitor-1; PEITC, phenethyl isocyanate; PI3K, phosphatidylinositol 3 kinase; PKC, protein kinase C; PT, Pterostilbene; RBPC, phenolic extracts derived from rice bran; ROS, reactive oxygen species; SAL, Salidroside; SFN, sulforaphane; SMT, Samul-Tang Tang; SOD, superoxide dismutase; Sal B, salvianolic acid B; SchB, Schisandrin B; TCM, traditional Chinese medicine; TNF, tumor necrosis factor; TXA2, Thromboxane A2; TrxR1, thioredoxin reductase-1; US, uraemic serum; VA, Vanillic acid; VCAM, vascular cell adhesion molecule; VEC, vascular endothelial cells; VEI, vascular endothelial injury; Vascular endothelial cells; XAG, xanthoangelol; XXT, Xueshuan Xinmaining Tablet; Z-Lig, Z-ligustilide; eNOS, endothelial NO synthase
Mesh:
Substances:
Year: 2021 PMID: 35024180 PMCID: PMC8655139 DOI: 10.1016/j.jare.2021.06.023
Source DB: PubMed Journal: J Adv Res ISSN: 2090-1224 Impact factor: 10.479
Fig. 1Endothelial cells play important role in maintaining vascular homeostasis. COX, cyclooxygenase; AA, arachidonic acid; PGI2, prostaglandin I2; EDHF, endothelium-derived hyperpolarizing factor; TXA2, Thromboxane A2; ET, endothelin; Ang II, Angiotensin II.
Fig. 2Nrf2/HO-1 signaling, oxidative stress and atherosclerosis.Nrf2, nuclear factor erythroid 2 related factor 2; HO-1, Heme Oxygenase 1; ROS, reactive oxygen species; ADP, adenosine diphosphate; TXA2, Thromboxane A2.
Protective effects of herbal medicine formulas on vascular endothelial cells.
| Extracts | Compositions | Animal/cells | Dose/Concentration | Effects | Related molecular targets | Refs. | |
|---|---|---|---|---|---|---|---|
| Up-regulation | Down-regulation | ||||||
| XXT | The roots of | H2O2 (200 μM) induced -HUVECs | 50,100,200 µg /mL | Increasing cell survival; Decreasing oxidative stress | Nrf2, HMOX, GCLM, NQO1 | ROS | 67 |
| LWDH | The roots of | Eahy 926 cells | 5%, 10%, 20% LWDH Medicated serum | Increasing cell proliferation | HO-1, p-ERK, Nrf2 | 68 | |
| SMT | TNF-α (50 ng/mL) induced HUVECs | 10,30,50 µg/mL | Inhibiting NF-κB translocation and activation, and expression of CAMs; Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | HO-1, Nrf2, NO | ROS, ICAM-1, VCAM-1, E-selectin; NF-κB-p65; p-IκBα | 69 | |
| Paeotang | TNFα (10 ng/mL) induced HUVECs | 10,20,50 µg/mL | Decreasing oxidative stress; Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | HO-1, Nrf2 | ROS, ICAM-1, VCAM-1, E-selectin, MMP-2, MMP-9, NF-κB-p65; p-IκB, Keap1 | 70 | |
| HXC | The roots of | H2O2 (0.2 mM) induced bEND.3 cells | 150,300,750 µg/mL | Increasing cell survival; Decreasing oxidative stress | HO-1, p-Akt, Nrf2 | 71 | |
HXC, Huoxue capsule; LWDH, Liuwei Dihuang Pill; SMT, Samul-Tang; XXT, Xueshuan Xinmaining Tablet.
Protective effects of herbal medicine extracts on vascular endothelial cells.
| Extracts | Animal/cells | Dose/Concentration | Effects | Related molecular targets | Refs. | |
|---|---|---|---|---|---|---|
| Up-regulation | Down-regulation | |||||
| GTE | PM2.5 (500, 1000 μg/mL) | 100 μg/ml | Decreasing oxidative stress; Reducing DNA damage; Reducing cell death and apoptosis; Improving vascular permeability | GSH, GR, SOD-1, HO-1, CAT | ROS, MDA, Caspase-3, Caspase-7, VEGFA | 73 |
| KRG | H2O2 (100 μM) induced HUVECs | 0.5,2 mg/mL | Decreasing oxidative stress; Reducing cell death | HO-1, Nrf2 | ROS | 74 |
| APV | HG (25 mM) induced - HUVECs | 10,30,50 µg/ml | Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | eNOS, HO-1, Nrf2, p-Akt | ICAM-1, VCAM-1, E-selectin, ROS, NF-κB-p65, p-IκBα, Keap 1, MMP-2, MMP-9 | 75 |
| TSAR | ox-LDL (100 μg/mL) induced HUVECs | 10,40,160 µg/mL | Increasing survival of HUVECs | NO | ET, LDH | 76 |
| EXS | TNFα (10 ng/mL) induced HUVECs | 1,10,50 μg/mL | Decreasing oxidative stress; Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | SOD, HO-1, Nrf2 | ICAM-1, VCAM-1, E-selectin, NF-κB-p65, p-IκBα | 77 |
| RBPC | H2O2 (200 μM) induced HUVECs | 25,50,100, 200 µg/mL | Decreasing oxidative stress; Decreasing vascular inflammation | Nrf2, NQO1, HO-1, eNOS | NOX4, ICAM1, CD39, CD73 | 78 |
| NAF | HG (25 mM) induced HUVECs | 50,10,150,200 µg/mL | Decreasing oxidative stress; Decreasing vascular inflammation | HO-1, Nrf2 | ICAM-1, VCAM-1, E-selectin, NF-κB-p65, p-IκBα, ROS | 79 |
APV, Prunella vulgaris; EXS, Xanthoceras sorbifolia; GDE, Ganoderma tsugae; GR, Glutathione Reductase; NAF, Nepeta angustifolia; RBPC, Rice Bran Phenolic Compounds; SMT, Samul-Tang; TSAR, Total saponins of Anemone raddeana Regel.
Protective effects of polysaccharides on vascular endothelial cells.
| Extracts | Animal/cells | Dose/Concentration | Effects | Related molecular targets | Refs. | |
|---|---|---|---|---|---|---|
| Up-regulation | Down-regulation | |||||
| ASTP | H2O2 (200 μM) induced HUVECs | 100, 200, 300 μM | Increasing cell survival; Reducing cell apoptosis | HO-1, KLF2, Nfr2, p-MEK, p-ERK | ROS, P53, p21, Bax, Caspase 9, Caspase 3 | 80 |
| AMCP | H2O2(300 μM) | 25–150 μg/mL | Reducing cell apoptosis | NO, SOD, CAT, MMP, PI3K, Akt, FOXO3a, Nrf2, HO-1, Bcl-2 | ROS, MDA, Bax | 81 |
| ASP | ox-LDL (200 μg/mL) induced HUVECs | 10,20,40 µg/mL | Increasing cell survival | eNOS, NO, VEGF, Akt | LDH, | 82 |
AMP, polysaccharide from Athyrium Multidentatum (Doll.) Ching; ASP, Angelica Sinensis Polysaccharide; ASTP, Astragalus polysaccharide; EXS, Xanthoceras sorbifolia.
Protective effects of monomers from herbal medicine on vascular endothelial cells.
| Classification/Monmers | Chemical Structure | Animal/cells | Dose/Concentration | Effects | Related molecular targets | Ref | |
|---|---|---|---|---|---|---|---|
| Up-regulation | Down-regulation | ||||||
| CINM | HG (30 mM) induced-HUVECs; HG (30 mM)- C57BL/6J mouse aortic rings | 10 μM | Protecting the endothelium relaxation; Decreasing oxidative stress | NO, Nrf2, HO-1, NQO1, CAT, GPx-1 | ROS, Nitrotyrosine | 86 | |
| H2O2 (350 μM) and TNF-α (10 ng/mL) induced- HUVECs | 20 µM | Inhibiting the adhesion of monocytes; Increasing cell survival; Reducing cell apoptosis; Decreasing vascular inflammation | HO-1, Nrf2, p-p38 | VCAM-1, ROS, c-PARP, NF-κB-p65 | 87 | ||
| Ferulic Acid | 10 Gy of 60Co source (1.64 Gy/min) induced-HUVECs | 0.2,1,5μM | Increasing cell survival; Decreasing oxidative stress | GSH, NADPH, Nrf2, GCLC, GCLM, NQO1, HO-1 | ROS | 88 | |
| Caffeic acid | HG (25 mM) induced-HUVECs | 10 nM | Increasing cell survival; Decreasing oxidative stress; Inhibiting the adhesion of monocytes | SOD, TAA, GSH, Nrf2, HO-1 | ROS, NF-κB-p65, E-selectin | 89 | |
| MCGA3 | t-BHP (1 mM) induced-HUVECs; | 0–200 μM | Increasing cell survival; Decreasing oxidative stress | HO-1, Ferritin, GCL, GR, GST, GSH, GSSG, Nrf2, p-JNK, p-ERK | ROS/LDH | 90 | |
| Echinacoside | HG (30 mM) induced-HUVECs | 200 μM | Decreasing oxidative stress | eNOS, HO-1, p-Akt, Nrf 2 | ROSFyn | 91 | |
| Sal B | t-BHP (800 μM) induced EA.hy926 cells | 50–400 μM | Reducing oxidative stress; activating Keap1-Nrf2-ARE signaling | HO-1, NQO1, Nrf2 | LDH, Keap1 | 92 | |
| SchB | LPS (1 μg/mL) induced-HUVECs | 10, 20, 40 μM | Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | Nrf2, HO-1 | TNF-α, IL-8, VCAM-1, ICAM-1, NF-κB-p65, p-IκBα | 93 | |
| Sauchinone | HG (25 mM) induced-HUVECs | 5,10,20,50 μM | Decreasing vascular inflammation | HO-1, Nrf2 | ROS, VCAM-1, ICAM-1, NF-κB-p65, p-IκBα | 94 | |
| 7-HMR | TNF-α (20 ng/mL) induced-RAECs | 100 μM | Decreasing vascular inflammation; Decreasing oxidative stress | SOD1, Nrf2, HO-1 | IL-6, VCAM-1, NLRP3, iNOS, NF-κB-p65, ROS, Keap1, p-ERK | 95 | |
| Curcumin | Co60 γ rays (Theratron 780, 0.6 Gy/min) induced- HUVECs | 5 µM | Inhibiting the adhesion of monocytes; Reducing DNA damage; Decreasing vascular inflammation | Nrf2, GSH | ICAM-1, VCAM-1, E-selectin, NF-κB-p65, IL-6, IL-8, MCP-1, 8-OHdG, TBARS | 97 | |
| Anthocyan | H2O2(400 μmol/L) induced-bEND.3 cells | 50,100 μg/mL | Reducing cell apoptosis; Decreasing oxidative stress | NO, SOD, GSH-PX, HO-1, Nrf2 | ROS, MDA, TNF-α, IL-6, LDH | 101 | |
| Hyperoxia (O2 32%) induced-HUVECs | 20% | Increasing cell survival | HO-1, Nrf2, NQO1, p-ERK1/2 | 102 | |||
| C3G | PA (100 μM) induced-HUVECs | 20,50 μM | Improving insulin resistance and vascular inflammation; Increasing vasodilatory activity | Nrf2, HO-1, p-Akt, p-eNOS | ET-1, PAI-1, p-IRS-1, p-IKK-β, p-JNK | 103 | |
| TNF-α (20 ng/mL) induced-HUVECs | 20,40 μM | Increasing cell survival; Decreasing vascular inflammation and oxidative stress | SOD, GSH, HO-1, NQO1, Nrf2, p-ERK | GSSG, NF-κB-p65 | 104 | ||
| PA (100 μM) induced-HUVECs | 20,50 μM | Increasing cell survival; Inhibiting monocytes adhesion; Decreasing vascular inflammation and oxidative stress | Nrf2, HO-1, NQO1, GSH | ROSVCAM-1, E-selectin, NF-κB-p65, Bch1 | 105 | ||
| ECC | H2O2 (100 μM) induced-HUVECs | 10 μM | Decreasing oxidative stress | HO-1 | ROS | 106 | |
| EGCG | microcystin-LR (40 μM) induced-HUVECs | 50 μM | Reducing cell apoptosis; Inhibiting mitochondrial dysfunction | MMP, Nrf2, HO-1 | Cyt c, Caspase 3, Caspase 9 | 107 | |
| Ang II (400 nmol/L) induced-HUVECs | 200 μM | Increasing cell survival; Reducing cell apoptosis; Decreasing oxidative stress; Inhibiting mitochondrial dysfunction | SOD, CAT, GST, GPx, MMP, Nrf2 | ROS, MDA, Cyt c, Caspase-3, Caspase-9, NOX | 108 | ||
| IL-1β (2 ng/mL) induced-HUVECs | 100 μM | Decreasing oxidative stress; Decreasing vascular inflammation | HO-1, SOD, Nrf2f | ROS, NF-κB-p65, p-IκBα, COX-2, PGE2, GPx | 109 | ||
| PM2.5(200 μg/mL) induced-HUVECs | 50,100,200 μg/mL | Increasing cell survival; Decreasing oxidative stress | HO-1, Nrf2 | ROS | 110 | ||
| Endothelial cells of porcine aorta | 30 μM | Increase bilirubin production | HO-1, Nrf2 | 111 | |||
| DHMT | Ox-LDL (70 μg/mL) induced-HUVECs | 40 μM | Increasing cell survival; Reducing cell apoptosis; Decreasing oxidative stress | MMP, SOD, CAT, GSH-Px, Bcl2, Nrf2, HO-1, p-ERK, p-Akt | ROS, MDA, Caspase 3, Caspase 9, Bax, LOX-1, Cyt c | 112 | |
| PA (300 μM) induced-HUVECs | 0.1, 0.5, 1 μM | Increasing cell survival; Reducing pyroptosis; Decreasing vascular inflammation | Nrf2, HO-1, NQO1 | ROS, Caspase1, IL-1β, NLRP3, p20, ICAM-1 | 113 | ||
| Kaempferol | ox-LDL (100 μg/mL) induced-HUVECs | 50 μg/mL | Increasing cell survival; Reducing cell apoptosis; Decreasing oxidative stress; Decreasing vascular inflammation | SOD, p-AMPK, Nrf2, HO-1, Bcl-2 | TNF-α, IL-1β, IL-6, ROS, Caspase3, ICAM-1, VCAM-1, E-selectin | 114 | |
| Fisetin | H2O2(300 μM) induced-HUVECs | 5,10,25 µM | Increasing cell survival; Decreasing oxidative stress; Reducing cell death | HO-1, Nrf2, HO, ARE | 115 | ||
| Myricitrin | H2O2 (600 μM) induced- ECV-304 cells | 16,32,64 μM | Reducing cell apoptosis; Decreasing oxidative stress | SOD, NO, Bcl-2, ERK | ROS, LDH, MDA, Bax, Caspase-9, Caspase-3, p-ERK | 116 | |
| Rutin | H2O2(200 μM) induced-HUVECs | 1,3,10,30 µM | Decreasing oxidative stress | Nrf2, GCLC | TrxR1, NF-κB-p65, HIF | 114 | |
| Eriodictyol | H2O2 (300 μM) induced-HUVECs | 10 μM | Decreasing oxidative stress; Reducing cell death | HO-1, HO, p-ERK, Nrf2, ARE | ROS | 118 | |
| Apigenin | AGEs (500 μg/mL) induced-HUVECs | 10 μM | Decreasing oxidative stress; Decreasing vascular inflammation | Nrf2, GCLM, GCLC, HO-1 | ROS, MCP-1, IL-6, ICAM1, TGF-β1, P22phox, RAGE, p-ERK, NF-κB-p65 | 119 | |
| Naringenin | HG (33 mM)/FFA(1 mM) induced-HUVECs | 0–100 μM | Reducing cell apoptosis | HO-1, p-Akt, p-ERK, p-JNK, Nrf2 | 120 | ||
| Baicalin | HG (22 mM) induced-HUVECs | 50 μM | Reducing cell apoptosis; Decreasing oxidative stress; Decreasing vascular inflammation | Bcl2, Nrf2, NQO1, NQO2, HO-1, CAT, SOD, p-Akt, p-GSK3B | Caspase3, Bax, IL-1β, IL6, IL8, TNF-α, n-Fyn | 121 | |
| Genistein | ox-LDL (100 mg/mL) induced-HUVECs | 1,10 μM | Increasing cell survival; Decreasing vascular inflammation | HO-1, Nrf2, HO | MCP-1, VCAM-1, ICAM-1 | 122 | |
| Equol | t-BHP (50 μM)/ thapsigargin (1 μM)/ PA (500 μM) induced- HUVECs apoE-/- mice | 1, 10, 100 nM | Alleviating AS plaque formation; Increasing cell survival; Reducing cell apoptosis; Attenuating ER stress | Nrf2, NQO1 | Caspase3, p-elF2α, p-PERK, GRP78, CHOP, ATF6 | 123 | |
| Phloretin | PA (100 μM) induced- HUVECs | 1, 10, 50 μM | Decreasing oxidative stress | MMP, SOD, Gpx-1, p-LKB1, p-AMPK, Nrf2, HO-1 | ROS, MDA | 124 | |
| Euxanthone | ox-LDL (100 μg/mL) induced-HUVECs | 5,10 μM | Increasing cell survival; Reducing cell apoptosis; Decreasing oxidative stress; Decreasing vascular inflammation | Bcl2, MMP, SOD, CAT, GSH-Px, Nrf2, HO-1, NQO1, p-ERK, p-P38, p-JNK | MDA, ROS, Caspase 3, PARP, Bax, Cyc c, Keap1, MCP-1, IL-1β, TNF-α | 125 | |
| XAG | ox-LDL (100 μg/mL) induced-HUVECs | 5 μM | Increasing cell survival; Reducing cell apoptosis; Decreasing oxidative stress | Bcl2, CAT, SOD, GSH-Px, Nrf2, HO-1, NQO1 | MDA, ROS, Caspase 3, PARP, Bax, Keap1 | 126 | |
| PMA | ox-LDL (70 μg/mL) induced-HUVECs | 10 μmol/L | Reducing cell apoptosis; Decreasing oxidative stress | SOD, Nrf2, HO-1, Caspase 3, Bcl2 | MDA, ROS, Bax | 129 | |
| Celastrol | Ang II (400 nM) induced-HUVECs | 50 nM | Increasing cell survival; Reducing cell apoptosis; Decreasing oxidative stress; Decreasing vascular inflammation | SOD, GSH-Px, p-ERK, Nrf2 | MDA, ROS, IL-6, TNF-α, VCAM, NADPH oxidase, NOX2, AT1 | 130 | |
| Oleanolic acid | ox-LDL (200 μg/mL) induced-HUVECs HFD-quails | 5,10,20 μmol/L | Increasing cell survival; Decreasing oxidative stress; Alleviating AS plaque formation | HO-1, Nrf2 | ROS, LOX-1, MADPH | 131 | |
| Maslinic acid | LPS ((1 μg/mL) induced-HUVECs | 2,5,10,20 μM | Decreasing oxidative stress; Decreasing vascular inflammation | NO, HO-1, Nrf2, ARE | COX-2, iNOS, PGE2, NF-κB-p65, IL-1β, p-STAT1 | 132 | |
| ASD IV | ox-LDL (100 μg/mL) induced-HUVECs | 10,20,50 μM | Increasing cell survival; Reducing cell apoptosis; Inhibiting cell migration; Decreasing vascular inflammation | Nrf2, HO-1 | MDA, ROS, NADPH oxidase, TNF-α, IL-6 | 133 | |
| GSD Rg1 | PM2.5 (400 μg/mL) induced-HUVECs | 2.5,10,40 μg/mL | Increasing cell survival; Decreasing oxidative stress | HO-1, Nrf2 | MDA, ROS | 134 | |
| ADH | TNF-α (1 ng/mL) induced-EA.hy926 cells | 7.5 μM | Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | GSH, GCLM, HO-1, p-Akt, p-ERK, Nrf2, c-Jun | ROS, ICAM-1 | 135 | |
| CoCl2 (200 μM) induced-EA.hy926 cells | 1.8,3.75,7.5 μM | Decreasing vascular inflammation | HO-1, PHD, Nrf2 | ROS, HIF-1α, ET-1, p-38 | 136 | ||
| Gau A | H2O2 (100 μM) induced-HUVECs | 0.1,0.5,1,10 μM | Decreasing vasoconstriction | eNOS | ET, iNOS | 137 | |
| ZAD | Ox-LDL (150 μg/mL) induced-HUVECs | 20 μg/mL | Increasing cell survival; Decreasing oxidative stress; Decreasing vascular inflammation | SOD, /Nrf2, HO-1, NQO1 | MDA, ROS, LOX-1, IL-1β, MCP-1, TNF-α, Keap1 | 138 | |
| Lycopene | Strain (20% in length, 1 Hz) induced-HUVECs | 3 μM | Decreasing oxidative stress | HO-1, Nrf2, p-Akt | ROS, ET-1, p22, NADPH oxidase, p-ERK | 139 | |
| Oxymatrine | HCS (3 mM) induced-HUVECs | 0.1, 0.3,0.6 µM | Decreasing oxidative stress; Increasing cell survival; Reducing cell apoptosis | NO, SOD, MMP/, Bcl2, Nrf2, p-Akt, p-eNOS | MDA, ROS, LDH, Bax, Caspase 9, Caspase 3 | 141 | |
| Corynoline | LPS (10 ng/ml) induced-HUVECs | 1,2,4µM | Increasing cell survival; Decreasing vascular inflammation | HO-1, Nrf2 | TNF-α, IL-6, IL-8, VCAM-1, ICAM-1, NF-κB-p65, p-IκBα | 142 | |
| Berberine | H2O2 (200 μM) induced-HUVECs | 5,10 μM | Reducing cell apoptosis | Nrf2, HO-1 | ROS | 143 | |
| BITC | Ox-LDL (40 µg/mL) induced-HUVECs | 2,5,10 µM | Inhibiting the adhesion of monocytes; Decreasing vascular inflammation; Decreasing oxidative stress | HO-1, GCLC, GCLM, GSH, Nrf2, ARE-driven | ROS, ICAM-1, VCAM-1, E-selectin/, NF-κB-p65, p-IκBα | 144 | |
| PEITC | Ox-LDL (40 µg/mL) induced-HUVECs | 2,5,10 µM | Inhibiting the adhesion of monocytes; Decreasing vascular inflammation; Decreasing oxidative stress | HO-1, GCLC, GCLM, GSH, Nrf2, ARE-driven | ROS, ICAM-1, VCAM-1, E-selectin, NF-κB-p65, p-IκBα | 145 | |
| Lotusine | H2O2 (400 μM) induced-ECV304 | 100 μM | Increasing cell survival | NOS, NO | 145 | ||
| Liensinine | H2O2 (400 μM) induced-ECV304 | 0.1 μM | Increasing cell survival | NOS, NO | 145 | ||
| Isoliensinine | H2O2 (400 μM) induced-ECV304 | 0.1 μM | Increasing cell survival | NOS, NO | 145 | ||
| Neferine | H2O2 (400 μM) induced-ECV304 | 0.1 μM | Increasing cell survival | NOS, NO | 145 | ||
| SFN | Ang II (400 nM) induced-HUVECs | 2 μM | Increasing cell survival; Reducing cell apoptosis; Inhibiting mitochondrial dysfunction; Decreasing oxidative stress | MMP, SOD, CAT, GSH, Nrf2, HO-1 | ROS, MDA, Cyt c, LDH, Caspase 3, Caspase 9, NADPH oxidase, GSSG | 146 | |
| Pterostilbene | US induced-HUVECs | 5,10,50 µM | Decreasing oxidative stress; Increasing cell survival; Decreasing vascular inflammation | SOD, CAT, eNOS, HO-1, Nrf2 | MDA, NADPH oxidase, iNOS,IL-1β, TNF-α, MCP-1, VCAM-1, Keap1, NOX | 148 | |
| AS-rat H2O2(300 μM) induced-HUVECs | Decreasing oxidative stress; Increasing cell survival; Reducing cell apoptosis; Reducing AS plaque size; Inhibiting of vascular wall apoptosis | Nrf2, p-AMPK | STAT3 | 149 | |||
| Resveratrol | H2O2 (300 μM) induced- HUVECs | 5,10,20 µM | Decreasing cell apoptosis; Activating PI3K-Akt-mTOR pathway; Decreasing oxidative stress; | SOD, GSH, p-Akt, p-mTOR, p-Nrf2 | ROS, MDA, LDH, Caspase-3, | 150,151 | |
| Miltirone | ox-LDL (120 μg/mL) induced-EA.hy926 cells | 0.5, 1, 2 µM | Increasing cell survival; Decreasing oxidative stress | Nrf2, ARE, HO-1, NQO1, SOD, GST, p-ERK, p-JNK | ROS, Keap1 | 152 | |
| Tanshinone IIA | HG (20 mM) induced-HUVECs | 10,30,50 μg/mL | Improving oxidative stres; Reducing lipid peroxidation and MDA; Enhancing activity of antioxidant enzyme; Increasing release of NO via regulation of Rho/Rho kinase system | NOS, SOD | ROS, ROCKI | 153 | |
| Withaferin A | HUVECs EA.hy926 | 1 µM | Increasing survival of HUVECs | HMOX1, HO-1, Nrf2 | Keap1 | 154 | |
| Z-Ligustilide | TNF-α (50 ng/ml) induced-HUVECs | 1, 3, 10 μM | Inhibiting the adhesion of monocytes; Decreasing vascular inflammation | NO, Nrf2, HO-1 | ROS, ICAM-1, VCAM-1, E-selectin, NF-κB-p65, p-IκBα | 155 | |
| t-BHP (200 μM) induced-EA.hy 926cells; | 100μΜ, 20 mg/kg | Increasing cell survival; Decreasing oxidative stress; Alleviating AS plaque formation | GSH, Nrf2, GCLM, HO-1, NQO1, SOD1, SOD2, CAT, GCLC, ARE-driven | GSSG, RO, Keap1 | 156 | ||
| Salidroside | H2O2 (300 μM) induced-HUVECs | 0.1,1,10 μM | Increasing cell survival; Decreasing oxidative stress | SOD, CAT, Nrf2, HO-1, NQO1 | ROS, MDA | 158 | |
| AGEs (200 μg/mL) induced-HUVECs | 0.1, 1, 10 μM | Protecting the endothelium relaxation; Decreasing oxidative stress; Decreasing vascular inflammation | NO, Nrf2, HO-1, NF-κB-p65 | ROS, Keap1 | 159 | ||
| Vanillic acid | PA (100 μM) induced-HUVECs | 1,10,20 µM | Decreasing oxidative stress | CAT, SOD, MMP, HO-1, Nrf2, p-LKB1, p-AMPK, SIRT1, PGC-1α | ROS, MDA | 160 | |
| PCA | PA (100 µM) induced-HUVECs | 100 µM | Decreasing oxidative stress; Increasing the mitochondrial density | SOD, HO-1, Gpx-1, p-LKB1, p-AMPK, Nrf2, PGC-1α | ROS, MDA | 161 | |
| Salicin | TNF-α (10 ng/mL) induced-HUVECs; | 50 and 100 μM | Inhibiting cellular senescence; preventing cell cycle arrest; Decreasing oxidative stress | Nrf2 | SAβ-Gal, P21, ROS, PAI-1, P53 | 162 | |
| Allicin | LPS (1 μg/mL) induced-HUVECs | 40 μg/mL | Increasing cell survival; Reducing cell apoptosis; Inhibiting mitochondrial dysfunction; Inhibiting the adhesion of monocytes; Decreasing oxidative stress; Decreasing vascular inflammation | SOD, CAT, GST, GPX, MMP, LXRα, Nrf2 | ROS, MDA, Cyt c, TNF-α, IL-8, NF-κB-p65 | 163 | |
| STZ-induced mice; | 30 mg/kg/d | Increasing cell survival; Reducing cell apoptosis; Decreasing vascular inflammation | Bcl2, Nrf2 | TNF-α, VCAM-1, Inos, MMP-2, MCP-1, Caspase 3, Bax, NF-κB-p65 | 164 | ||
AMP, polysaccharide from Athyrium Multidentatum (Doll.) Ching; ASP, Angelica Sinensis Polysaccharide; ASTP, Astragalus polysaccharide; EXS, Xanthoceras sorbifolia 7-HMR, (−)-7(S)-hydroxymatairesinol; ADH, Andrographolide; ASD IV, Astragaloside IV; BITC, Benzyl isothiocyanate; C3G, Cyanidin-3-O-glucoside; CFA, Caffeic acid; CINM, Cinnamaldehyde; DHMT, Dihydromyricetin; ECC, (−)-epicatechin; EGCG, Epigallocatechin-3-gallate; ET, endothelin; FAD, Ferulic Acid; FFA, free fatty acids; Gau A, glaucocalyxin A; GSD Rg1, Ginsenoside Rg1; HCS, Homocysteine; HFD, High fat diet; HG, high glucose; MCGA3, 3-O-caffeoyl-1-methylquinic acid; MSA, Maslinic Acid; OLA, Oleanolic acid; PA, palmitic acid; PCA, Protocatechuic acid; PEITC, phenethyl isocyanate; PMA, Pachymic acid; RAECs, rat aortic endothelial cells; Sal B, Salvianolic acid B; SchB, Schisandrin B; SFN, (−)-Sulforaphane; STZ, Streptozotocin; t-BHP, tert-butyl hydroperoxide; US, uraemic serum; VNA, Vanillic acid; XAG, Xanthoangelol; ZAD, Zedoarondiol.
Fig. 3The possible molecular mechanisms for herbal medicines to protect vascular endothelial cells via activation of Nrf2/HO-1 signaling.